Abstract
Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis that killed an estimated 4000-5000 person each day during 2005. Although infections with drug sensitive strains can be effectively cured with a 6 to 9 month regimen of multiple antibiotics, the inability to deliver and complete appropriate courses of therapy on a global level has led to the selection of resistant strains over the past 50 years. The selection and spread of multiple drug resistant M. tuberculosis continued for decades leading to two operationally distinct forms of the disease, multiple drug resistant (MDR-TB) and extensively drug resistant (XDR-TB). The estimate for MDR-TB and XDR-TB cases for 2005 were 424,000 and 27,000 respectively, and the situation is worst in areas with high incidences of HIV infection. The outcome was predictable based on basic microbiological principles, and the resultant and future epidemic effectively modeled mathematically. This situation was brought to the forefront when an outbreak of XDR-TB occurred in Tugela Ferry, KwaZulu- Natal, South Africa, in 2005 and began to spread. Unfortunately, we do not know the true extent of XDR-TB globally. However, all signs point to an emerging epidemic of TB infections that will be difficult, if not impossible to cure. A few new drugs are in clinical trials, but it is too early to know the final outcome; some may fail, and none will be available for several years. The situation will continue to worsen unless more resources are made available to discover and deliver better treatment options.
Keywords: XDR-TB, extensively drug resistant, tuberculosis, MDR-TB, Mycobacterium
Infectious Disorders - Drug Targets
Title: The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control
Volume: 7 Issue: 2
Author(s): Robert C. Goldman, Kevin V. Plumley and Barbara E. Laughon
Affiliation:
Keywords: XDR-TB, extensively drug resistant, tuberculosis, MDR-TB, Mycobacterium
Abstract: Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis that killed an estimated 4000-5000 person each day during 2005. Although infections with drug sensitive strains can be effectively cured with a 6 to 9 month regimen of multiple antibiotics, the inability to deliver and complete appropriate courses of therapy on a global level has led to the selection of resistant strains over the past 50 years. The selection and spread of multiple drug resistant M. tuberculosis continued for decades leading to two operationally distinct forms of the disease, multiple drug resistant (MDR-TB) and extensively drug resistant (XDR-TB). The estimate for MDR-TB and XDR-TB cases for 2005 were 424,000 and 27,000 respectively, and the situation is worst in areas with high incidences of HIV infection. The outcome was predictable based on basic microbiological principles, and the resultant and future epidemic effectively modeled mathematically. This situation was brought to the forefront when an outbreak of XDR-TB occurred in Tugela Ferry, KwaZulu- Natal, South Africa, in 2005 and began to spread. Unfortunately, we do not know the true extent of XDR-TB globally. However, all signs point to an emerging epidemic of TB infections that will be difficult, if not impossible to cure. A few new drugs are in clinical trials, but it is too early to know the final outcome; some may fail, and none will be available for several years. The situation will continue to worsen unless more resources are made available to discover and deliver better treatment options.
Export Options
About this article
Cite this article as:
Robert C. Goldman , Kevin V. Plumley and Barbara E. Laughon , The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001844
DOI https://dx.doi.org/10.2174/187152607781001844 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Therapeutic Potential of Piperine: A Comprehensive Review
The Natural Products Journal Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine The Treatment of Tubal Inflammatory Infertility using Yinjia Tablets through EGFR/MEK/ERK Signaling Pathway based on Network Pharmacology
Current Pharmaceutical Biotechnology When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Current Respiratory Medicine Reviews Fostemsavir: A Novel CD4 Attachment Inhibitor for Heavily Treated HIV-1 Patient
Current Indian Science From Conformation to Interaction: Techniques to Explore the Hsp70/ Hsp90 Network
Current Protein & Peptide Science Advances in the Development of Potential Anti-Invasive Drugs and Strategies Focused on Overcoming Drug Resistance
Current Medicinal Chemistry Epidemiology of HIV in Iran
Current HIV Research Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Nanodelivery Systems for Improved Topical Antimicrobial Therapy
Current Pharmaceutical Design Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery Perspectives and Prospects on mRNA Vaccine Development for COVID-19
Current Medicinal Chemistry Microwave Assisted Vilsmeier-Haack Reaction on Substituted Cyclohexanone Hydrazones: Synthesis of Novel 4,5,6,7-Tetrahydroindazole Derivatives
Letters in Organic Chemistry Virtual Screening of Novel Phytocompound(s) with Potential to Combat <i>Mycobacterium tuberculosis</i> Infection
Letters in Drug Design & Discovery Multiplication of <i>Mycobacterium tuberculosis</i> in Peripheral Blood of Mice and Effect of Anti-tubercular Drugs on Bacteremia
Letters in Drug Design & Discovery Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection
Current Pharmaceutical Design Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Development of a Multi-Compartmental Oral Vaccine Delivery System
Drug Delivery Letters